10-Q: Myomo Inc. Q1 2026 Revenue Up 3%, Net Loss Widens

Myomo Inc. reported a 3% increase in Q1 2026 revenue to $10.11 million, but net loss widened to $3.01 million, impacted by increased operating expenses and derivative liability revaluation.

Summary

• Myomo Inc. reported Q1 2026 revenue of $10.11 million, a 3% increase from $9.83 million in Q1 2025.
• The company experienced a net loss of $3.01 million for Q1 2026, compared to a net loss of $3.47 million in the prior year period.
• Gross profit increased by 4% to $6.90 million, with gross margin improving to 68.2% from 67.2%.
• Operating expenses increased slightly by 1% to $10.06 million, driven by a 10% rise in selling, clinical, and marketing expenses.
• Research and development expenses decreased by 9% to $1.62 million.
• General and administrative expenses decreased by 8% to $3.62 million.
• The company ended the quarter with $11.40 million in cash and cash equivalents.
• The company has secured a $17.5 million loan facility with Avenue Capital Management II, L.P., with $12.5 million funded at closing.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment, as revenue growth is modest and the net loss persists, despite a favorable revaluation of derivative liabilities.

Positives

• Revenue increased by 3% to $10.11 million in Q1 2026.
• Gross profit increased by 4% to $6.90 million.
• Gross margin improved to 68.2% from 67.2% in the prior year period.
• Selling, clinical, and marketing expenses are expected to have a lower growth rate in 2026.
• General and administrative expenses decreased by 8% to $3.62 million.
• The company has a $17.5 million loan facility, providing access to capital.
• The company believes its available cash, cash equivalents, and short-term investments will fund operations for at least the next twelve months.

Negatives

• Net loss widened to $3.01 million in Q1 2026 from $3.47 million in Q1 2025.
• Operating expenses increased by 1% to $10.06 million.
• Selling, clinical, and marketing expenses increased by 10% to $4.82 million.
• The company continues to incur net losses and negative cash flows from operations.
• The company's business is dependent on reimbursement from insurance companies and government plans, which could impact revenue growth.
• The fair value of derivative liabilities decreased, resulting in a significant gain that masked the underlying operational loss.

Risks

• The company's ability to achieve or obtain sufficient reimbursement from third-party payers for its products.
• Dependence upon external sources for financing operations.
• Ability to scale the business to return to positive cash flow from operations.
• Revenue concentration with patients who have Medicare Part B insurance coverage.
• Ability to continue normal operations and patient interactions without supply chain disruption.
• Effectiveness of marketing and commercialization efforts.
• Ability to obtain and maintain strategic collaborations and realize their intended results.
• Ability to effectively execute the business plan and scale up operations.
• Product development programs, including improving existing products and developing new products.
• Ability to maintain and grow reputation and achieve market acceptance of products.
• Clinical research program and clinical results.
• Ability to maintain adequate protection of intellectual property and avoid violation of others' intellectual property rights.
• Ability to gain and maintain regulatory approvals.
• Ability to compete and succeed in a highly competitive and evolving industry.
• General market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of products.
• Significant political, trade, regulatory developments, and other circumstances beyond the company's control.
• Failure to properly manage anticipated growth, including in the O&P channel and international markets.
• Risks associated with selling products internationally, including compliance with foreign laws, currency fluctuations, and political instability.

Future Outlook

The company expects revenues to continue to grow in 2026, driven by investments in recurring revenue sources like the MyoConnect program and O&P practices, aiming to reduce reliance on advertising-driven direct-to-patient revenues. Management plans to reduce the growth rate of selling, clinical, and marketing expenses and minimize the growth of fixed expenses. The company anticipates continuing to incur net losses and negative cash flows from operations in 2026.

Management Comments

• Management believes that available cash, cash equivalents, and short-term investments will fund operations for at least the next twelve months.
• Management's operating plans are focused on growing revenues from recurring sources, expanding the MyoConnect program, and continued growth in the O&P channel and international operations, while reducing patient acquisition costs and minimizing fixed expense growth.
• Management believes it has access to capital resources through possible public or private equity offerings, or other means.
• Management intends to manage R&D expenses in 2026 while maintaining the pace of R&D efforts.
• Management expects the growth rate in selling, clinical, and marketing expenses to be lower in 2026.
• Management intends to reduce the growth rate in general and administrative expenses in 2026.

Industry Context

StockSavvy.ai notes that Myomo's Q1 2026 results reflect ongoing challenges in the medical device sector, particularly concerning reimbursement reliance and the transition to new revenue models. The increase in revenue, while positive, is tempered by widening losses, a common theme for companies investing heavily in market expansion and product development in a competitive landscape.

Comparison to Industry Standards

• The gross margin of 68.2% is strong for a medical device company, often exceeding the industry average which can range from 40-60% depending on the sub-sector.
• The company's continued net loss, while concerning, is not uncommon for early-stage or growth-focused medical technology firms that are investing heavily in R&D, sales, and market penetration, similar to companies like Intuitive Surgical in its earlier years.
• The reliance on Medicare Part B reimbursement (51% of revenue) highlights a common industry challenge where regulatory changes and payment determinations significantly impact financial performance, a factor also faced by other durable medical equipment providers.

Legal Proceedings

• There are no material claims, assessments or litigation against the Company as of March 31, 2026.

Stakeholder Impact

• Shareholders: Continued net losses and reliance on external financing may impact stock value. Potential for future equity offerings could dilute existing shareholders.
• Employees: Continued investment in R&D and sales may lead to job creation, but ongoing losses could pose job security concerns.
• Customers: Continued product development and potential for improved reimbursement could benefit patients.
• Creditors: The new loan facility provides some comfort, but the company's ability to service debt depends on future performance.
• Suppliers: Increased demand from growth in O&P channel and international markets may increase business for suppliers, but also requires careful management of supply chain.

Next Steps

• Focus on growing revenues from recurring sources, including the MyoConnect referral program and O&P practices in the U.S. and Germany.
• Implement marketing initiatives to reduce Cost Per Pipeline Add in the direct billing channel.
• Minimize the growth of fixed expenses.
• Continue to manage R&D expenses while maintaining the pace of R&D efforts.
• Invest in the MyoConnect referral program, including clinical sales personnel.
• Support international operations and the O&P channel.
• Potentially explore strategic alternatives for the purpose of maximizing stockholder value.

Key Dates

Recommendation

The company shows modest revenue growth and improved gross margins, but continues to operate at a significant net loss. The new loan facility provides some liquidity, but the reliance on Medicare reimbursement and the ongoing investment in growth initiatives create uncertainty. A 'hold' recommendation is appropriate given the mixed financial performance and the need to see sustained improvement in profitability and cash flow.

Keywords

Myomo, 10-Q, Quarterly Report, Medical Robotics, Orthotics, Neuromuscular Disorders, MyoPro, Wearable Medical Device, Revenue, Net Loss, Financial Statements, SEC Filing, Medicare Reimbursement, Avenue Capital